CGD Policy Experts Discuss COVID-19 Vaccine Trial Results, Implications For LMICs

Center for Global Development: Monday Morning Vaccine Breakthrough: Terrific News for the West, but in LMICs Terms and Conditions Apply
Rachel Silverman, policy fellow with CGD, discusses Pfizer’s and BioNTech’s announcement that “their SARS-CoV2 vaccine candidate showed 90 percent efficacy in preventing symptomatic COVID-19 in the interim analysis of their late stage clinical trial,” and highlights three challenges: distribution, cold-chain supply, and feasibility of future efficacy trials for other vaccine candidates (11/9).

Center for Global Development: Don’t Cheer Yet — There Is Too Much at Stake on COVID-19 Vaccines
Kalipso Chalkidou, director of global health policy and senior fellow at CGD, urges caution over the vaccine trial results, highlights lessons from remdesivir trials, and discusses implications for LMICs (11/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.